 ROCKVILLE, MD, Feb. 11, 2021 GLOBE NEWSWIRE -- MacroGenics, Inc. Nasdaq: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica Freddi OBrien, President of CFOBrien Consulting, LLC, to its Board of Directors. 